Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 721 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo, Part B Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide (LY3298176) in Healthy Participants

NCT03375463
View directory record Official record
Conditions
Healthy
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

NCT02626026
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tirabrutinib, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 4, 2026, 12:02 AM EDT
Active, not recruiting Phase 2 Interventional

Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

NCT06503978
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
4 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 4, 2026, 12:02 AM EDT
Terminated Phase 3 Interventional

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

NCT02326740
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
gevokizumab, Placebo, gevokizumab open-label
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Oceanside, California • Tampa, Florida • Macon, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Sep 4, 2026, 12:02 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

NCT05231785
View directory record Official record
Conditions
Early-Onset Alzheimer Disease
Interventions
ALN-APP, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
La Jolla, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 2 Interventional Results available

Ghrelin (OXE--103) for Acute Concussion Management

NCT04558346
View directory record Official record
Conditions
Concussion, Brain, Traumatic Brain Injury
Interventions
Ghrelin (OXE-103), Placebo
Drug
Lead sponsor
Michael Rippee
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 1 Interventional

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

NCT00314782
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054 (Zibotentan), Docetaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Buffalo, New York • Greenville, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

NCT03881059
View directory record Official record
Conditions
Active Psoriatic Arthritis
Interventions
BMS-986165 Placebo, BMS-986165 Dose A, BMS-986165 Dose B, Ustekinumab, Ustekinumab Placebo
Other · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
31
States / cities
Huntsville, Alabama • Covina, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 4, 2026, 12:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

SAD and MAD Study of FTX-101 in Healthy Male Subjects

NCT06617546
View directory record Official record
Conditions
Healthy Volunteers
Interventions
FTX-101, Placebo
Drug
Lead sponsor
Find Therapeutics
Industry
Eligibility
18 Years to 59 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 4, 2026, 12:02 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787182
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma

NCT02748642
View directory record Official record
Conditions
Mild Atopic Asthma
Interventions
BITS7201A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Results available

Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop

NCT02328040
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo and Insulin monotherapy via CL, Sitagliptin and insulin/novolog via CL
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
14 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants

NCT07566130
View directory record Official record
Conditions
Healthy Volunteers
Interventions
nacresertib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

NCT04313400
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2
Drug
Lead sponsor
Amytrx Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Cerritos, California • Encino, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 4, 2026, 12:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

NCT02614131
View directory record Official record
Conditions
Healthy, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
LY2599666, Solanezumab, Placebo SC, Placebo IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Glendale, California • Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 4, 2026, 12:02 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

NCT06843590
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
34
States / cities
Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 4, 2026, 12:02 AM EDT
Recruiting Phase 1 Interventional

A Study of LY3971297 in Participants With Heart Failure

NCT07547540
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Interventions
LY3971297, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Detroit, Michigan • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

NCT05169671
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ATH-1020, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

NCT02325791
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Up to 6 Months
Enrollment
1,177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
107
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Sep 4, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

NCT05845645
View directory record Official record
Conditions
Healthy Study Participants
Interventions
UCB0599, Esomeprazole, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 4, 2026, 12:02 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

NCT07772531
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BMS-986511, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 4, 2026, 12:02 AM EDT